Systematic overview of drug interactions with antidepressant medications.
OBJECTIVE
Antidepressants are commonly used drugs with potential for numerous drug interactions. This study aims to systematically review the literature on drug interactions with antidepressants.


METHODS
We searched MEDLINE (1966 to November 2003) and EMBASE (1980 to 2003), using the heading drug interactions combined with individual antidepressant names. We restricted searches to English-language articles and human studies. We screened drug interaction texts and review articles for relevant studies. We included articles reporting original human data on drug interactions with antidepressants commonly used in North America. Articles were independently evaluated by 2 reviewers on clinical effect, clinical significance, and quality of evidence. Discrepancies were resolved by consensus.


RESULTS
There were 904 eligible interactions, involving 9509 patients, for a total of 598 summary interactions. Of these, 439 (73%) demonstrated an interaction, 148 (25%) had no effect, and 11 (2%) had conflicting evidence. For 510 interactions (85%), the quality of evidence was poor. It was fair for 67 (11%) interactions and good for 10 (2%) interactions. There were no interactions with excellent quality of evidence. There were 145 (24%) interactions of major clinical significance. These were predominantly hypertensive emergencies and serotonin syndrome. Most interacting drugs had central nervous system (CNS) activity. As expected, monoamine oxidase inhibitors (MAOIs) appear to be the most problematic family in terms of potential for serious drug interactions.


CONCLUSIONS
Drug interactions with antidepressants are an important cause for concern, but this concern is based primarily on poor evidence. We recommend caution when combining antidepressants with other CNS drugs, particularly when coadministering MAOIs with other substances.
Nieuwstraten
Carmine
C
St. Joseph's Healthcare, Hamilton, Ontario.
Labiris
N Renee
NR
Holbrook
Anne
A
D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D004358:Drug Therapy / Q000401:mortality; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D020902:Hypericum; D006973:Hypertension / Q000453:epidemiology*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D008517:Phytotherapy; D020230:Serotonin Syndrome / Q000453:epidemiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D003577:Cytochrome P-450 Enzyme System; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors